ORIC PHARMACEUTICALS, INC. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
ORIC PHARMACEUTICALS, INC. (ORIC) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $436.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-21.
Discontinued › Cash Flow
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2022-03-21
- ORIC PHARMACEUTICALS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-12-31 was $394.00K.
- ORIC PHARMACEUTICALS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-09-30 was $14.00K, a 86.67% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-06-30 was -$50.00K.
- ORIC PHARMACEUTICALS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-03-31 was $78.00K, a 22.77% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2021 was $436.00K, a 913.95% increase from fiscal 2020.
- ORIC PHARMACEUTICALS, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2020 was $43.00K.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2021-12-31 | $394.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $408.00K derived: sum of 2 quarters · filed 2022-03-21 | $358.00K derived: sum of 3 quarters · filed 2022-03-21 | $436.00K 10-K · filed 2022-03-21 |
| 2021-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$36.00K derived: sum of 2 quarters · filed 2021-11-08 | $42.00K 10-Q · filed 2021-11-08 | -$47.00K derived: sum of 4 quarters · filed 2022-03-21 |
| 2021-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $28.00K 10-Q · filed 2021-08-10 | -$61.00K derived: sum of 3 quarters · filed 2022-03-21 | $44.00K derived: sum of 4 quarters · filed 2022-03-21 |
| 2021-03-31 | $78.00K 10-Q · filed 2021-05-06 | -$11.00K derived: sum of 2 quarters · filed 2022-03-21 | $94.00K derived: sum of 3 quarters · filed 2022-03-21 | $20.00K derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $16.00K derived: sum of 2 quarters · filed 2022-03-21 | -$58.00K derived: sum of 3 quarters · filed 2022-03-21 | $43.00K 10-K · filed 2022-03-21 |
| 2020-09-30 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $31.00K derived: sum of 2 quarters · filed 2021-11-08 | $132.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $27.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $101.00K 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | -$182.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$124.00K derived: sum of 2 quarters · filed 2020-11-05 | $11.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $193.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $135.00K 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |